A Phase I Study of Famitinib Malate in Patients With Solid Tumor
Latest Information Update: 27 Sep 2023
Price :
$35 *
At a glance
- Drugs Famitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 23 Jan 2013 New trial record